吉西他滨区域性动脉灌注联合全身化疗治疗晚期胰腺癌

目的:评价吉西他滨区域性动脉灌注联合全身化疗对晚期胰腺癌的治疗效果。方法:对13例经手术病理或临床证实的晚期胰腺癌患者采用5-FU+MMC行静脉化疗,以介入方法用吉西他滨作区域性动脉灌注化疗。结果:13例可评价疗效者中部分缓解（PR）4例,病情进展（SD）6例,PD3例;临床受益反应评价有效率为76.9％;疼痛缓解率75.0%。中位生存时间为6.3个月,所有患者未出现严重毒副反应。结论:吉西他滨区域性动脉灌注联合全身化疗可缓解晚期胰腺癌患者癌性疼痛,改善患者一般状态,提高生存质量,延长生存期,且患者耐受良好。

Therapeutic effects of gemcitabine regional artery perfusion combined with systemic chemotherapy for late-stage cancer of pancreas

Objective To evaluate the therapeutic effects of gemcitabine regional artery perfusion combined with systemic chemotherapy for late-stage cancer of pancreas.Methods Thirteen cases of late-stage cancer of pancreas proven by operation and pathology were treated with 5-FU MMC as a combined system chemotherapy, and use of gemcitabine for regional artery perfusion chemotherapy.Results Among the 13 patients who could be evaluated for therapeutic effect, four cases had partial response (PR), six cases had (SD), three cases were PD, and the effective rate of the clinical benifical-reflected evaluation was 76.9%, pain releive rate 75.0% the median survival time was 6.3 months. None of the patients have had serious toxious side-effects.Conclusions The gemcitabine regional artery perfusion combined with systemic chemotherapy can relieve the cancer pain of patients with late-stage cancer of pancreas, improve their general condition, increase the survival quality of life, prolong the survival time. The drug tolerance of the patients is good.